Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.38
- Piotroski Score 3.00
- Grade Buy
- Symbol (AYTU)
- Company Aytu BioPharma, Inc.
- Price $1.51
- Changes Percentage (1.91%)
- Change $0.03
- Day Low $1.45
- Day High $1.55
- Year High $3.45
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/05/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.44
- Trailing P/E Ratio -1.24
- Forward P/E Ratio -1.24
- P/E Growth -1.24
- Net Income $-15,844,000
Income Statement
Quarterly
Annual
Latest News of AYTU
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Aytu BioPharma Inc (AYTU) Q1 2025 Earnings Call Highlights: A Historic Quarter with Positive ...
The company is expanding its ADHD franchise reach through various strategies like leveraging unique distributors, RS Connect network pharmacies, and nonpersonal promotion tactics. Pediatric scripts ha...
By Yahoo! Finance | 1 week ago -
AYTU Stock Price | Aytu BioPharma Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
Aytu Biopharma, Inc. is a specialty pharmaceutical company focused on acquiring and commercializing novel products. It operates in Rx and Consumer Health segments, offering a range of prescription and...
By MarketWatch | 1 week ago -
Aytu BioPharma Names Ryan Selhorn as CFO
Ryan Selhorn has been appointed as Aytu BioPharma's CFO, treasurer, and corporate secretary, effective Nov. 11, succeeding Mark Oki. Selhorn previously held various finance roles and will earn an annu...
By MarketWatch | 1 week ago
